Insulin receptor and cancer.

@article{Belfiore2011InsulinRA,
  title={Insulin receptor and cancer.},
  author={Antonino Belfiore and Roberta Malaguarnera},
  journal={Endocrine-related cancer},
  year={2011},
  volume={18 4},
  pages={
          R125-47
        }
}
The widespread epidemic of obesity and type 2 diabetes has raised concern for the impact of these disorders as risk factors for cancer and has renewed the interest for studies regarding the involvement of hyperinsulinemia and insulin receptor (IR) in cancer progression. Overexpression of IR in cancer cells may explain their increased sensitivity to hyperinsulinemia. Moreover, IR isoform A (IR-A) together with autocrine production of its ligand IGF2 is emerging as an important mechanism of… 

Figures and Tables from this paper

Insulin Receptor Isoforms in Cancer

The insulin receptor (IR) mediates both metabolic and mitogenic effects especially when overexpressed or in clinical conditions with compensatory hyperinsulinemia, due to the metabolic pathway

Insulin and IGFs in Obesity-Related Breast Cancer

The focus of this review is the insulin-family and its role has been supported by preclinical studies and the importance of insulin resistance and hyperinsulinemia in obesity and early diabetes.

PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis

The use of PPAR-γ agonists in combined therapies of IGF-driven malignancies looks promising but requires future developments.

Insulin signaling network in cancer.

How the insulin enacts such diverse physiological effects and the insulin-cancer relationship is discussed, with focus on the role of insulin signaling in cancer.

The Role of Metabolic Factors in Renal Cancers

It seems that the monitoring of health conditions, such as diabetes, low body mass index (BMI), and lipid disorders is of high importance in clear-cell RCC.

Rethinking the Relationship between Insulin and Cancer

A Twenty-First Century Cancer Epidemic Caused by Obesity: The Involvement of Insulin, Diabetes, and Insulin-Like Growth Factors

The molecular basis of the involvement of morbidly high concentrations of endogenous or therapeutic insulin and of insulin-like growth factors in the progression from obesity to diabetes and finally to cancer is reviewed.

Effect of insulin on thyroid cell proliferation, tumor cell migration, and potentially related mechanisms

The in vitro evidence demonstrated that HI and IG can promote thyroid cell proliferation and tumor cell migration at supraphysiological concentrations, but the effect was not significant at low concentrations.

The Links Between Insulin Resistance, Diabetes, and Cancer

This review endeavored to synthesize the recent literature and provide a concise view of the journey from macro-level clinical associations to specific mechanistic relationships being elucidated in cell lines and animal models.
...

References

SHOWING 1-10 OF 245 REFERENCES

The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer.

  • A. Belfiore
  • Biology, Medicine
    Current pharmaceutical design
  • 2007
The concept that hyperinsulinemia, associated with insulin resistance and obesity, should be treated by changes in life style and/or pharmachological approaches to avoid an increased risk for cancer is underline.

Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.

These findings offer compelling experimental evidence that T2D accelerates mammary gland development and carcinogenesis, and that the IR and/or the IGF-IR are major mediators of these effects.

The relation of type 2 diabetes and cancer.

The consistent positive results reported by prospective investigations make it unlikely that methodologic issues, occult tumors, or chance results could explain the findings, and the findings are evaluated in terms of well- accepted criteria for establishing causality.

Insulin Receptor What Role in Breast Cancer?

The role of the IGF system in cancer growth and metastasis: overview and recent insights.

The review highlights the importance of viewing the IGF axis as a complex multifactorial system and shows that changes in the expression levels of any one component of the axis, in a given malignancy, should be interpreted with caution and viewed in a wider context that takes into account the expression Levels, state of activation, accessibility, and functionality of other interacting components.

Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling

It is indicated that tumors with low IGF-1R:IR ratio are unlikely to greatly benefit from anti-IGF- 1R therapies and that the efficacy of anti-igF-1r therapies should be evaluated in relationship to the IR-A:IGF -1R ratio in cancer cells.

Metformin and reduced risk of cancer in diabetic patients

It is hypothesised that metformin use in patients with type 2 diabetes may reduce their risk of cancer and tested this hypothesis using record linkage databases developed in Tayside, Scotland: a diabetes clinical information system (DARTS) and a database of dispensed prescriptions (MEMO).

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

P-IGF-IR/IR could be a predictive marker for response to IGF-IR and/or IR-targeted therapies, as these inhibitors may be of benefit in all breast cancer subtypes including those with acquired resistance to tamoxifen.

The insulin-like growth factor-I receptor as an oncogene

The underlying molecular mechanisms that are responsible for the normal, physiological control of IGF-IR gene expression, as well as the cellular pathways that underlie its aberrant expression in cancer are focused on.

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

TZD use was associated with reduced risk of lung cancer, and this was observed among TZD users compared with nonusers after adjusting for confounder interactions.
...